Clinical Trial Update: 64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial of MM-302 in advanced HER2-positive cancers with brain metastases has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Cancer

Drugs mentioned

• MM-302 (liposomal doxorubicin (HER2-targeted))

Snippet

Sponsor: Pamela Munster | Conditions: Brain Metastases, Documented Her2 Overexpression | EARLY_Phase 1 | Status: WITHDRAWN